Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Public ClinicalTrials.gov record NCT02149108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
Study identification
- NCT ID
- NCT02149108
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 768 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2014 (Actual)
- Primary completion
- May 13, 2016 (Actual)
- Completion
- Aug 25, 2016 (Actual)
- Last update posted
- Jul 21, 2017
2014 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1199.52.0108 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1199.52.0105 Boehringer Ingelheim Investigational Site | New Haven | Connecticut | — | — |
| 1199.52.0101 Boehringer Ingelheim Investigational Site | Plainville | Connecticut | — | — |
| 1199.52.0121 Boehringer Ingelheim Investigational Site | Arlington Heights | Illinois | — | — |
| 1199.52.0123 Boehringer Ingelheim Investigational Site | Sioux City | Iowa | — | — |
| 1199.52.0104 Boehringer Ingelheim Investigational Site | Topeka | Kansas | — | — |
| 1199.52.0114 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1199.52.0113 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 1199.52.0125 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1199.52.0119 Boehringer Ingelheim Investigational Site | Johnson City | New York | — | — |
| 1199.52.0115 Boehringer Ingelheim Investigational Site | Canton | Ohio | — | — |
| 1199.52.0106 Boehringer Ingelheim Investigational Site | Sylvania | Ohio | — | — |
| 1199.52.0102 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 1199.52.0120 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02149108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02149108 live on ClinicalTrials.gov.